TY - JOUR
T1 - Renal tumors
T2 - diagnostic and prognostic biomarkers
AU - Tan, Puay Hoon
AU - Cheng, Liang
AU - Rioux-Leclercq, Nathalie
AU - Merino, Maria J.
AU - Netto, George
AU - Reuter, Victor E.
AU - Shen, Steven S.
AU - Grignon, David J.
AU - Montironi, Rodolfo
AU - Egevad, Lars
AU - Srigley, John R.
AU - Delahunt, Brett
AU - Moch, Holger
AU - Delprado, Warick
AU - Maclean, Fiona
AU - The ISUP Renal Tumor Panel
PY - 2013
Y1 - 2013
N2 - The International Society of Urological Pathology convened a consensus conference on renal cancer, preceded by an online survey, to address issues relating to the diagnosis and reporting of renal neoplasia. In this report, the role of biomarkers in the diagnosis and assessment of prognosis of renal tumors is addressed. In particular we focused upon the use of immunohistochemical markers and the approach to specific differential diagnostic scenarios. We enquired whether cytogenetic and molecular tools were applied in practice and asked for views on the perceived prognostic role of biomarkers. Both the survey and conference voting results demonstrated a high degree of consensus in participants' responses regarding prognostic/ predictive markers and molecular techniques, whereas it was apparent that biomarkers for these purposes remained outside the diagnostic realm pending clinical validation. Although no individual antibody or panel of antibodies reached consensus for classifying renal tumors, or for confirming renal metastatic disease, it was noted from the online survey that 87% of respondents used immunohistochemistry to subtype renal tumors sometimes or occasionally, and a majority (87%) used immunohistochemical markers (Pax 2 or Pax 8, renal cell carcinoma [RCC] marker, panel of pan-CK, CK7, vimentin, and CD10) in confirming the diagnosis of metastatic RCC. There was consensus that immunohistochemistry should be used for histologic subtyping and applied before reaching a diagnosis of unclassified RCC. At the conference, there was consensus that TFE3 and TFEB analysis ought to be requested when RCC was diagnosed in a young patient or when histologic appearances were suggestive of the translocation subtype; whereas Pax 2 and/ or Pax 8 were considered to be the most useful markers in the diagnosis of a renal primary.
AB - The International Society of Urological Pathology convened a consensus conference on renal cancer, preceded by an online survey, to address issues relating to the diagnosis and reporting of renal neoplasia. In this report, the role of biomarkers in the diagnosis and assessment of prognosis of renal tumors is addressed. In particular we focused upon the use of immunohistochemical markers and the approach to specific differential diagnostic scenarios. We enquired whether cytogenetic and molecular tools were applied in practice and asked for views on the perceived prognostic role of biomarkers. Both the survey and conference voting results demonstrated a high degree of consensus in participants' responses regarding prognostic/ predictive markers and molecular techniques, whereas it was apparent that biomarkers for these purposes remained outside the diagnostic realm pending clinical validation. Although no individual antibody or panel of antibodies reached consensus for classifying renal tumors, or for confirming renal metastatic disease, it was noted from the online survey that 87% of respondents used immunohistochemistry to subtype renal tumors sometimes or occasionally, and a majority (87%) used immunohistochemical markers (Pax 2 or Pax 8, renal cell carcinoma [RCC] marker, panel of pan-CK, CK7, vimentin, and CD10) in confirming the diagnosis of metastatic RCC. There was consensus that immunohistochemistry should be used for histologic subtyping and applied before reaching a diagnosis of unclassified RCC. At the conference, there was consensus that TFE3 and TFEB analysis ought to be requested when RCC was diagnosed in a young patient or when histologic appearances were suggestive of the translocation subtype; whereas Pax 2 and/ or Pax 8 were considered to be the most useful markers in the diagnosis of a renal primary.
KW - CK7
KW - Immunohistochemistry
KW - International Society of Urological Pathology
KW - Pax 2
KW - Pax 8
KW - Renal cell carcinoma
KW - Translocation carcinoma
UR - http://www.scopus.com/inward/record.url?scp=84900393064&partnerID=8YFLogxK
U2 - 10.1097/PAS.0b013e318299f12e
DO - 10.1097/PAS.0b013e318299f12e
M3 - Article
C2 - 24025522
AN - SCOPUS:84900393064
SN - 0147-5185
VL - 37
SP - 1518
EP - 1531
JO - American Journal of Surgical Pathology
JF - American Journal of Surgical Pathology
IS - 10
ER -